Skip to main content
. 2023 May 18;59(5):972. doi: 10.3390/medicina59050972

Table 1.

This table outlines the PICO model followed.

  • 1.

    Participants/population: patients at high-risk or with medication-related osteonecrosis of the jaw (MRONJ) disease

  • 2.

    Intervention/exposure: autologous platelet concentrates (APCs) and/or laser treatment for MRONJ prevention and/or treatment.

  • 3.

    Comparison/control: no comparison.

  • 4.

    Outcomes: the role of APCs and/or laser for MRONJ prevention or treatment, enhanced healing, or lower rates or no recurrence of MRONJ disease.